Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benztropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benztropine SCHEMBL8659140 | 1.00 | DRD2 (1.00) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| Benztropine SCHEMBL5960155 | 1.00 | DRD2 (1.00) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| Benztropine SCHEMBL35390 | 1.00 | DRD2 (1.00) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| Benztropine SCHEMBL35388 | 1.00 | DRD2 (1.00) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| Benztropine SCHEMBL4152475 | 0.98 | DRD2 (0.97) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| SCHEMBL8697606 | 0.91 | DRD2 (0.83) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| SCHEMBL2615299 | 0.91 | CHRM1 (0.89) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| Clobenztropine SCHEMBL1152891 | 0.91 | DRD3 (1.00) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| SCHEMBL2615297 | 0.91 | CHRM1 (0.89) | DRD2DRD3SLC6A2CHRM2CHRM4 | |
| Clobenztropine SCHEMBL137213 | 0.91 | DRD3 (1.00) | DRD2DRD3SLC6A2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11076 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-4706766-A2 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | ADS Therapeutics LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705484-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAU-RELATED DISORDERS | Voyager Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705485-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | Voyager Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-1989012470-A1 | SUBSATURATED TRANSDERMAL DELIVERY DEVICE | ALZA CORPORATION (US) | 1989-12-28 | — | — | WO | claimed |
| WO-1989005641-A1 | DEXTROMETHORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD | PONTECORVO MICHAEL J (US) | 1989-06-29 | — | — | WO | claimed |
| US-4837027-A | THERAPEUTIC AGENT STORED AS SALT, MOISTURE ACTIVATES | ALZA CORPORATION (US) | 1989-06-06 | — | — | US | claimed |
| EP-0316065-A2 | Improved transdermal drug delivery device | ALZA CORPORATION (US) | 1989-05-17 | — | — | EP | claimed |
| US-4788063-A | FATTY ACID, CHOLINERGIC OR ANTICHOLINERGIC AGENT | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1988-11-29 | — | — | US | claimed |
| US-4781924-A | RELEASE BY MOISTURE ACTIVATOR | ALZA CORPORATION (US) | 1988-11-01 | — | — | US | claimed |
| EP-0233932-A4 | ANTICONVULSANT COMPOSITIONS AND METHOD. | UNIV NEW YORK (US) | 1988-04-26 | — | — | EP | claimed |
| EP-0233932-A1 | ANTICONVULSANT COMPOSITIONS AND METHOD | NEW YORK UNIVERSITY (US) | 1987-09-02 | — | — | EP | claimed |
| WO-1987001036-A1 | ANTICONVULSANT COMPOSITIONS AND METHOD | NEW YORK UNIVERSITY (US) | 1987-02-26 | — | — | WO | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |